Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate

Journal of Neuroimmunology

Volumn 167, Issue 1-2, 2005, Pages 215-218

  Azoulay, David ^a   Vachapova, Veronika ^a   Shihman, Boris ^a   Miler, Ariel ^b   Karni, Arnon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Brain derived neurotrophic factor; Glatiramer acetate; Multiple sclerosis; Neuroprotection

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLATIRAMER;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPROTECTION; PRIORITY JOURNAL; RELAPSE; REMISSION; SERUM;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 24144469398     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2005.07.001     Document Type: Article

References (13)

1. R. Aharoni, B. Kayhan, R. Eilam, M. Sela, and R. Arnon Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ Proc. Natl. Acad. Sci. U. S. A. 100 2003 14157 14162
2. M. Besser, and R. Wank Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors J. Immunol. 162 1999 6303 6306
3. C.F. Brosnan, and C.S. Raine Mechanisms of immune injury in multiple sclerosis Brain Pathol. 6 1996 243 257
4. B. Connor, and M. Dragunow The role of neuronal growth factors in neurodegenerative disorders of the human brain Brain Res. Brain Res. Rev. 27 1998 1 39
5. Y. Ge, R.I. Grossman, J.K. Udupa, J. Fulton, C.S. Constantinescu, F. Gonzales-Scarano, J.S. Babb, L.J. Mannon, D.L. Kolson, and J.A. Cohen Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment Neurology 54 2000 813 817
6. R. Hohlfeld, M. Kerschensteiner, C. Stadelmann, H. Lassmann, and H. Wekerle The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis J. Neuroimmunol. 107 2000 161 166
7. M. Kerschensteiner, E. Gallmeier, L. Behrens, V.V. Leal, T. Misgeld, W.E. Klinkert, R. Kolbeck, E. Hoppe, R.L. Oropeza-Wekerle, I. Bartke, C. Stadelmann, H. Lassmann, H. Wekerle, and R. Hohlfeld Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 189 1999 865 870
8. M. Lommatzsch, A. Braun, A. Mannsfeldt, V.A. Botchkarev, N.V. Botchkareva, R. Paus, A. Fischer, G.R. Lewin, and H. Renz Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived neurotrophic functions Am. J. Pathol. 155 1999 1183 1193
9. O. Neuhaus, C. Farina, A. Yassouridis, H. Wiendl, F. Then Bergh, T. Dose, H. Wekerle, and R. Hohlfeld Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells Proc. Natl. Acad. Sci. U. S. A. 97 2000 7452 7457
10. M. Rovaris, G. Comi, M.A. Rocca, J.S. Wolinsky, and M. Filippi Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications Brain 124 2001 1803 1812
11. C. Stadelmann, M. Kerschensteiner, T. Misgeld, W. Bruck, R. Hohlfeld, and H. Lassmann BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125 2002 75 85
12. J.A. Vega, O. Garcia-Suarez, J. Hannestad, M. Perez-Perez, and A. Germana Neurotrophins and the immune system J. Anat. 203 2003 1 19
13. T. Ziemssen, T. Kumpfel, W.E. Klinkert, O. Neuhaus, and R. Hohlfeld Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor Brain 125 2002 2381 2391